Eledon reports updated Phase 1b data for tegoprubart; eGFR ~68 at 12 months, predicted 5-year graft survival >96%

Eledon Pharmaceuticals, Inc.

On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².
Preliminary abbreviated iBox score -4.11 (on-treatment) vs -2.98 historical CNI; predicts 5-year graft survival >96%.
No deaths, graft loss, drug-related tremor, or new-onset diabetes; six rejection episodes (18.8%), all successfully treated.
Patients who remained on tegoprubart after rejection had mean eGFR ~73 mL/min/1.73m² at 12 months; switched to tacrolimus had ~34.
Topline results from Phase 2 BESTOW trial comparing tegoprubart to tacrolimus expected in November 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.